Secukinumab (AIN457) 抗 IL-17 藥物 | abmole貨號M1622

代理廠牌：
原廠連結：
相關下載：

特點

Secukinumab (AIN457) 抗 IL-17 藥物| abmole貨號M1622
Cat. No. M1622

Secukinumab (AIN457) 是一種針對白細胞介素 (IL-17A) 的高親和力單克隆抗體。 Secukinumab (AIN457) 是斑塊狀銀屑病、強直性脊柱炎和銀屑病關節炎研究中的一流抗 IL-17 藥物。

Biological Activity

Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is a first-in-class anti-IL-17 agent in the study of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.

Chemical Information

Molecular Weight	147941.89
Formula	C6584H10134N1754O2042S44
CAS Number	875356-43-7
Storage	-80°C for long term

Conversion of different model animals based on BSA (PMID: 27057123)

Species	Mouse	Rat	Rabbit	Guinea pig	Hamster	Dog
Weight (kg)	0.02	0.15	1.8	0.4	0.08	10
Body Surface Area (m²)	0.007	0.025	0.15	0.05	0.02	0.5
K_m factor	3	6	12	8	5	20

Animal A (mg/kg) = Animal B (mg/kg) multiplied by	Animal B K_m
	Animal A K_m

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the K_m factor for a mouse and then divide by the K_m factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Kristian Reich, et al. N Engl J Med. Bimekizumab versus Secukinumab in Plaque Psoriasis

[2] Hannah A Blair. Drugs. Secukinumab: A Review in Psoriatic Arthritis

[3] Hannah A Blair. Drugs. Secukinumab: A Review in Ankylosing Spondylitis

[4] Lubrano E, et al. Ther Clin Risk Manag. Secukinumab for ankylosing spondylitis and psoriatic arthritis.

[5] Dominique Baeten, et al. N Engl J Med. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

[6] Richard G Langley, et al. N Engl J Med. Secukinumab in plaque psoriasis–results of two phase 3 trials

↑回到頁首↑